PubMed COVID-19 Clinical Care

Viral protein prods nerve cells, may be treatment target.

Antiviral drugs reduce the rate of progression to severe COVID-19 when given to patients with mild-to-moderate disease within 5 days of symptom onset. Despite being recommended for patients at high risk for progression to severe COVID-19 because of

BACKGROUND: The medical residency application process is daunting, time-consuming, and variable, making mentorship in preparation for this process important. In light of changes to the residency application process due to the COVID-19 pandemic

BACKGROUND: Health and care workers (HCW) faced the double burden of the SARS-CoV-2 pandemic: as members of a society affected by a public health emergency and as HWC who experienced fear of becoming infected and of infecting others, stigma, violence

CONCLUSION: This study will provide important information on the long-term effects of a lower versus a higher oxygenation target on long-term cognitive and pulmonary functions in adult ICU patients with acute hypoxaemic respiratory failure.

CONCLUSIONS: Our findings may inform the development of healthcare system and organisational policies to ensure the provision of maternal and newborn care in the event of future public health emergencies. Of primary importance to the participants was

CONCLUSION: Multiple prevalence of COVID-19 disease were found in employees of the internal, surgical and rehabilitation departments in whom we detected a higher presence of IgG antibodies. In department of laboratory medicine workers were proven

CONCLUSIONS: Significantly increased neutrophil NETosis, reduced NETosis reserve, and enhanced thrombus formation under arterial shear may play a crucial role in pathogenesis of COVID-19 associated coagulopathy. Recombinant ADAMTS13 or caplacizumab

CONCLUSION: The results showed a relationship between the number of positive cases of COVID-19 and the environmental parameters of temperature and humidity in five departments in the province of Catamarca.

CONCLUSION: The study concluded that the IFNL1 SNP (rs30461) may constitute an independent risk factor for COVID-19 severity.